Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meloxicam PK and Food Effect Study
NCT02181309Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2002
- Primary completion
- Apr 2002
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of meloxicam in osteoarthritis (OA) and rheumatoid arthritis (RA) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum drug plasma concentration up to 96 hours and Area under the plasma concentration-time curve from time to administration to infinity up to 96 hours. Started Jan 2002; status: completed.
02
Drugs
meloxicam
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02181309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02181309.